Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Cardioselective beta-blocker (β1 + β2 partial agonist)

Celiprolol hydrochloride

Brand names: Celectol

Celiprolol is a cardioselective beta-blocker with partial beta-2 agonist and weak vasodilator activity, used in the management of hypertension.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively blocks beta-1 adrenoceptors to reduce heart rate and cardiac output while exerting partial beta-2 agonism that contributes to peripheral vasodilatation.

Prescribing in practice

  • As with other beta-blockers, avoid abrupt withdrawal, which can precipitate rebound angina, arrhythmia or myocardial infarction; taper gradually.
  • Use with caution in patients with a history of obstructive airways disease, and avoid in unstable or uncontrolled heart failure.
  • Absorption is reduced when taken with food, so consistent timing in relation to meals is advised; consult current prescribing references.

Monitoring

Monitor blood pressure and heart rate, with clinical assessment for signs of heart failure or bronchospasm.

Counselling the patient

  • Do not stop this medicine suddenly without medical advice.
  • Report breathlessness, wheeze, marked dizziness or a very slow pulse.
  • Take it consistently with respect to meals as advised.

Evidence & guidelines

Beta-blockers are an established option in the management of hypertension within NICE guidance, generally after other first-line agents.

Reference: NICE NG136; RCP / EDS guidance; ESC HT; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways